GlassScriptPhysician profile
Asha L Bailey
NPI 1619156957
$5,084.68
in general payments reported to CMS, 2019-2025
35 companies · $902 in 2025
The $902 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $228 · 2021: $609 · 2022: $415 · 2023: $1,109 · 2024: $1,064 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640 · Education: $181 · Travel and Lodging: $143 · Consulting Fee: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.44 |
| Education | $181.13 |
| Travel and Lodging | $143.30 |
| Consulting Fee | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.09 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Novartis Pharmaceuticals Corporation | $602.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $387.03 | 2019-2024 | Benlysta, Jesduvroq |
| Amgen INC. | $383.91 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $352.42 | 2020-2024 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $352.12 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $294.41 | 2019-2023 | Veltassa |
| Calliditas Therapeutics US INC. | $284.49 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $218.00 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Enterprises LLC | $162.49 | 2019 | |
| Horizon Therapeutics Plc | $144.07 | 2019-2023 | Krystexxa |
| Abbott Laboratories | $133.24 | 2019 | |
| Akebia Therapeutics INC | $132.73 | 2020-2024 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $126.11 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $105.69 | 2019-2024 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $97.48 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $93.46 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.44 | 2021-2023 | |
| Ardelyx, INC. | $75.66 | 2023-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $69.44 | 2023 | |
| Novo Nordisk INC | $67.93 | 2024-2025 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $65.30 | 2020-2023 | Rayaldee |
| Lundbeck LLC | $39.28 | 2019 | |
| Scpharmaceuticals INC. | $37.15 | 2025 | |
| Genzyme Corporation | $35.37 | 2019-2023 | |
| Daiichi Sankyo INC. | $30.02 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $26.15 | 2025 | Empaveli |
| Lilly USA, LLC | $19.44 | 2024 | Jardiance |
| Kyowa Kirin, INC. | $18.09 | 2023 | Crysvita |
| Vbi Vaccine (Delaware) INC. | $17.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.28 | 2025 | Jardiance |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.